Dulpatatug clinical trials
Also written HLX22.
How each study uses dulpatatug is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the dulpatatug studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HLX22
- 5
Studies by the year they started
7 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Shanghai Henlius Biotech (6) · Shanghai Zhongshan Hospital (1)
Often tested with
Tested in the same studies.
HLX87 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test dulpatatug, phase 3 first.
- Jun 2027A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerPhase 3 · Shanghai Henlius Biotech
- Mar 2027A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and ChemotherapyPhase 2 · Shanghai Zhongshan Hospital
- Jun 2027A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer PatientsPhase 2 · Shanghai Henlius Biotech
Studies
Open first, then newest update. How each study uses dulpatatug is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer PatientsNot yet recruitingPhase 2Shanghai Henlius BiotechNCT07824869Written as HLX22
- A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast CancerRecruitingPhase 2/3Shanghai Henlius BiotechNCT07294508Written as HLX87 + HLX22
- A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingPhase 3Shanghai Henlius BiotechNCT06532006Written as HLX22
- A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer PatientsRecruitingPhase 2Shanghai Henlius BiotechNCT06832202Written as HLX22
- A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and ChemotherapyActive, not recruitingPhase 2Shanghai Zhongshan HospitalNCT07176702Written as HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy
- Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric CancerActive, not recruitingPhase 2Shanghai Henlius BiotechNCT04908813Written as HLX22
- Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2CompletedPhase 1Shanghai Henlius BiotechNCT03916094Written as HLX22
Codes
What other systems call dulpatatug · ClinicalTrials.gg INT016936
- UNII (FDA) JC6L2E97Q8DULPATATUGOne source FDA
- NCI Thesaurus C172198DulpatatugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | JC6L2E97Q8 | DULPATATUG | One source FDA |
| NCI Thesaurus | C172198 | Dulpatatug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.